The cost-utility of treating anemia with continuous erythropoietin receptor activator or Epoetin versus routine blood transfusions among chronic hemodialysis patients

OBJECTIVE: The purpose of this study was to determine the cost-utility of treating anemic dialysis patients with continuous erythropoietin receptor activator (CERA) once monthly or Epoetin Beta (EpoB) thrice weekly compared with a reference strategy of managing anemia with red blood cell transfusion...

Descripción completa

Detalles Bibliográficos
Autores principales: Maoujoud, Omar, Ahid, Samir, Cherrah, Yahia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771395/
https://www.ncbi.nlm.nih.gov/pubmed/26966386
http://dx.doi.org/10.2147/IJNRD.S96027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771395/
https://www.ncbi.nlm.nih.gov/pubmed/26966386
http://dx.doi.org/10.2147/IJNRD.S96027

Ejemplares similares